All the Drug Class Drugs
anti-CD3. Tarlatamab 1 mg, 10 mg. Vial 1X Pwder. for conc. for sol. for infus.
Cycle 1, day 1: 1mg, days 8, 15 : 10 mg
Cycle 2 and follow.: days 1, 15: 10 mg. See lit.
Adlt. pts. with extensive stage small cell lung cancer (ES-SCLC) with dis. progress. on or after platinum-based chemother.
C/I:Hypersens.
anti-CD3, Antineoplastic, Monoclonal Antibody. Teclistamab 10 mg/ml, 90 mg/ml. VIAL Sol. for inj.3 ml
Recomm. doses are 1.5 mg/kg by SC inj. weekly, preceded by step-up doses of 0.06 mg/kg and 0.3 mg/kg. See full prescr. info.
As monother. for adults with relapsed and refractory multiple myeloma, who have received at least 3 prior ther., incl. an immunomodulatory agent, a proteasome inhibit., and an anti-CD38 antibody and have demonstrated dis. progress. on the last ther.
C/I:Hypersens.
Anti-CD20, anti-CD3. Epcoritamab 5 mg/ml, 60 mg/ml. Vial, Sol. for inj. 1 X 4 mg/0.8 ml or 48 mg
To be admin in cycles of 28 days as per full prescription info. Pre-medication needed.
For adults with relapsed or refractory diffuse large B-cell
lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high grade B cell lymphoma after two or more lines of syst. ther.
As monother. for adults with relapsed or refractory follicular
lymphoma (FL) after two or more lines of syst. ther/
C/I: Hypersens.
